News briefing: 10 years later, teplizumab gets a second shot at an FDA OK; J&J files for amivantamab approval in Europe
Teplizumab’s 10-year trek back into the R&D spotlight is getting another assist from the FDA.
The agency has provided a brief priority review schedule for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
